Case report describes refractory MOGAD treatment using combined immunotherapy, suggesting new therapeutic directions.
To describe a refractory case of myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and the importance of a multimodal immunotherapeutic strategy that targets B cells, T cells, and cytokine pathways in cases resistant to standard treatment.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: